Join the Oncology Voice Network. Join for Free
Busting Silos: Building the Future of Oncology Drug Development

Busting Silos: Building the Future of Oncology Drug Development


Share This Article


Summary

In our premiere episode, Dr. Ramin Farhood, along with Dr. Kirk Shepard, shares the origin story behind the Oncology Voice Network (OVN)—a bold vision to unite pharma, biotech, academia, and advocacy, breaking down silos that have slowed progress for years.

What does it mean to give oncology drug development a “home”? 

 

In our premiere episode, Dr. Ramin Farhood, along with Dr. Kirk Shepard, shares the origin story behind the Oncology Voice Network (OVN)—a bold vision to unite pharma, biotech, academia, and advocacy, breaking down silos that have slowed progress for years.

 

Hear how the book ‘Voices of Oncology’ inspired conversations among industry leaders, and discover how those insights gave rise to a living, breathing network built on shared knowledge and real collaboration.

 

See how OVN is redefining what’s possible in cancer innovation. Listen to #OncologyVoiceNetwork now!

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Explore OVN